Greater China Equity Long/Short Analyst

Eric Chen

Equity Bottom-Up

Alibaba Group Holding  / Equity Bottom-Up

<ul>
<li>Alibaba is transforming into a leaner, more efficient and more profitable technology company with sharpened focus on core business and shareholder return.</li>
<li>While we don’t expect growth to define the company in the near future, high single-digit P/E more than compensates for the lack of it.</li>
<li>This worst-performing and cheapest technology stock among global peers stands a big chance of staging a comeback in 2024 in our view.</li>
</ul>


Alibaba is transforming into a leaner, more efficient and more profitable technology company with sharpened focus on core business and shareholder return.
While we don’t expect growth to define the company in the near future, high single-digit P/E more than compensates for the lack of it.
This worst-performing and cheapest technology stock among global peers stands a big chance of staging a comeback in 2024 in our view.


Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Alibaba Group Holding Limited delivered a mixed set of results for the previous quarter, with revenues below the analyst consensus.</li><li>For Taobao and Tmall Group, the emphasis lies on user-centric strategies, universal market coverage, multi-tiered consumer engagement, and maintaining price competitiveness.</li><li>The Local Services Group concentrates on location-based technology services, with Amap focusing on mobility and Ele.me on-demand services.</li></ul>

Alibaba Group Holding Limited delivered a mixed set of results for the previous quarter, with revenues below the analyst consensus.For Taobao and Tmall Group, the emphasis lies on user-centric strategies, universal market coverage, multi-tiered consumer engagement, and maintaining price competitiveness.The Local Services Group concentrates on location-based technology services, with Amap focusing on mobility and Ele.me on-demand services.

Alibaba Group Holding Limited: Can Their Upgraded AI Model To Challenge Microsoft & Amazon? - Major Drivers

Equity Analyst, LightStream Research

Oshadhi Kumarasiri

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

<ul>
<li>In the latest wave of management changes, Eddie Wu, Jack Ma’s trusted associate has staged a comeback, securing pivotal roles.</li>
<li>We believe this is not a mere coincidence. Jack Ma seems to be orchestrating moves from behind the scenes, with Eddie Wu strategically positioned to represent his influence.</li>
<li>The Chinese government's reaction to Jack Ma's increased involvement may impact <a href="https://www.smartkarma.com/entities/alibaba-group-holding-ltd-d7b798e2-202d-4e01-9a1e-799e2ae8f0c7" target="_blank" data-smartkarma-citation="entities:28434:1" rel="noopener">Alibaba Group Holding (9988 HK)</a>'s price performance in the short term.</li>
</ul>


In the latest wave of management changes, Eddie Wu, Jack Ma’s trusted associate has staged a comeback, securing pivotal roles.
We believe this is not a mere coincidence. Jack Ma seems to be orchestrating moves from behind the scenes, with Eddie Wu strategically positioned to represent his influence.
The Chinese government's reaction to Jack Ma's increased involvement may impact Alibaba Group Holding (9988 HK)'s price performance in the short term.


Alibaba’s Eddie Wu, Strategic Leader or Ma's Partner?

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.</li>
<li>GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.</li>
<li>In this note, we will talk about the company’s past performance and future prospects.</li>
</ul>


Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.
GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
In this note, we will talk about the company’s past performance and future prospects.


2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

<ul>
<li>Positive surprises in profitability during Q1 2023 failed to reverse the long-term decline of Chinese e-commerce, possibly due to market recognition of the temporary impact of cost-cutting and monetization efforts.</li>
<li>In our opinion, robust growth in GMV is fundamentally essential to reverse the long-term downward trend of the Chinese e-commerce sector.</li>
<li>Chinese e-commerce sector no longer discloses GMV, but Express delivery volume indicates a 20% decline in parcel volumes compared to 2021, potentially reflecting a decrease in GMV.</li>
</ul>


Positive surprises in profitability during Q1 2023 failed to reverse the long-term decline of Chinese e-commerce, possibly due to market recognition of the temporary impact of cost-cutting and monetization efforts.
In our opinion, robust growth in GMV is fundamentally essential to reverse the long-term downward trend of the Chinese e-commerce sector.
Chinese e-commerce sector no longer discloses GMV, but Express delivery volume indicates a 20% decline in parcel volumes compared to 2021, potentially reflecting a decrease in GMV.


China

Alibaba Group Holding Limited provides online sales services. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alibaba Group Holding (BABA US)

Alibaba (BABA US): No Where to Go but Up

Alibaba is embarking on a strategic transformation to become leaner, more efficient and more profitable, prioritizing core business and...

Eric Chen

Alibaba Group Holding Limited: Can Their Upgraded AI Model To Challenge Microsoft & Amazon? - Major Drivers

Alibaba Group Holding Limited delivered a mixed set of results for the previous quarter, with revenues below the analyst consensus. For Taobao and...

Baptista Research

Alibaba’s Eddie Wu, Strategic Leader or Ma's Partner?

Jack Ma's trusted associate, Eddie Wu, has returned to a pivotal role, suggesting that Ma is orchestrating moves behind the scenes and positioning...

Oshadhi Kumarasiri

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Sumeet Singh

China E-Commerce: Is Still a Dead Cat

Positive surprises in profitability in Q1 failed to reverse the long-term decline of Chinese e-commerce, possibly due to market recognition of the...

Oshadhi Kumarasiri

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Alibaba (BABA US): No Where to Go but Up

​Alibaba is embarking on a strategic transformation to become leaner, more efficient and more profitable, prioritizing core business and...

Eric Chen

Alibaba Group Holding Limited: Can Their Upgraded AI Model To Challenge Microsoft & Amazon? - Major Drivers

Alibaba Group Holding Limited delivered a mixed set of results for the previous quarter, with revenues below the analyst consensus. For Taobao and...

Baptista Research

Alibaba’s Eddie Wu, Strategic Leader or Ma's Partner?

​Jack Ma's trusted associate, Eddie Wu, has returned to a pivotal role, suggesting that Ma is orchestrating moves behind the scenes and positioning...

Oshadhi Kumarasiri

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Sumeet Singh

China E-Commerce: Is Still a Dead Cat

Positive surprises in profitability in Q1 failed to reverse the long-term decline of Chinese e-commerce, possibly due to market recognition of the...

Oshadhi Kumarasiri

Alibaba is embarking on a strategic transformation to become leaner, more efficient and more profitable, prioritizing core business and...

Jack Ma's trusted associate, Eddie Wu, has returned to a pivotal role, suggesting that Ma is orchestrating moves behind the scenes and positioning...